Recent 8-K filings for GYRE

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 12, 2026 21:03 UTC regulatory item 7.01item 9.01

  Gyre Therapeutics' NDA for F351 accepted by China's NMPA for CHB-induced liver fibrosis

source · GYRE on sec.gov